Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Alkaloid Synthesis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN119954798A offers high purity Berberine Hydrochloride synthesis. Reduces heavy metal risks and improves supply chain reliability for pharmaceutical intermediates.
Patent CN100361993C details a novel pyrrole-based route yielding high-purity brominated aldisin derivatives with reduced costs and improved supply chain reliability for global pharmaceutical manufacturing.
Novel double dearomatization method for spiro-indolizidines. High yield up to 95%. Cost-effective route for API intermediates without precious metals.
Patent CN1789247A details a high-yield stereospecific route for chiral N-acylpiperidines. Discover cost-effective manufacturing and scalable supply chain solutions for complex alkaloid intermediates.
Novel pyrrole-based route for Aldisin synthesis offering higher yield and safer solvents. Ideal for reliable API intermediate supply chains and cost reduction.
Patent CN102153501B reveals a metal-free organocatalytic route for chiral pyrrolidines and piperidines, offering significant cost reduction in API manufacturing and supply chain reliability.
Patent CN102153501A details a metal-free organocatalytic synthesis of chiral pyrrolidines and piperidines with high enantioselectivity, offering cost-effective routes for pharmaceutical intermediates.
Patent CN114874139A details a green visible-light method for synthesizing dihydroisoquinoline intermediates, offering cost reduction and scalable supply chain solutions for pharmaceutical manufacturing.
Patent CN114874139A details a green visible-light method for 1-benzyl-3,4-dihydroisoquinoline. Offers cost-effective, scalable pharma intermediate production.
Patent CN114874139A details a green visible-light method for synthesizing 1-benzyl-3,4-dihydroisoquinolines, offering cost-effective routes for pharmaceutical intermediates.
Solve high catalyst cost & low ee in chiral α-aminophosphonic acid synthesis. Our CDMO expertise delivers 99% ee with 0.0001% catalyst loading. Scale to 100 MT/yr.